ghk cu tolerance desensitization downregulation long term use effectiveness loss Frontiers April 2026 Commercial

April 2026 Commercial

Key Research Findings Cardiolipin Stabilization — SS-31 binds to cardiolipin through electrostatic and hydrophobic interactions, preventing cytochrome c peroxidase activity and preserving cristae structure and electron transport chain efficiency in isolated mitochondrial preparations Mitochondrial ROS Reduction — In vitro and in vivo studies demonstrate SS-31 reduces mitochondrial reactive oxygen species production at Complex I and III without acting as a direct free radical scavenger Cardiac Ischemia-Reperfusion — Preclinical rodent and large animal models of myocardial infarction show SS-31 reduces infarct size, preserves left ventricular function, and attenuates mitochondrial damage when administered during reperfusion Barth Syndrome Research — Phase II clinical trials (TAZPOWER) investigated SS-31 in patients with Barth syndrome, a genetic cardiolipin deficiency, providing key data on cardiolipin-targeted therapy Age-Related Mitochondrial Decline — Rodent aging studies demonstrate SS-31 restores mitochondrial function, improves ATP production, and reverses age-related declines in cardiac and skeletal muscle performance Specifications Reported Side Effects in Research Injection site reactions (pain, erythema, induration) reported as the most common adverse event in clinical trials Transient headache and dizziness observed in Phase II study participants Renal effects (increased serum creatinine) observed in some clinical contexts, particularly at higher doses This product is intended strictly for laboratory and research purposes only

Our Products

Options:Buy 4 Get 8 Free

At the same time, they are investing in technology, particularly AI and digital experiences, to drive future growth and competitive positioning.